Haemonetics Co. (NYSE:HAE) Short Interest Update

Haemonetics Co. (NYSE:HAE - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 4,530,000 shares, a drop of 24.9% from the March 15th total of 6,030,000 shares. Approximately 9.1% of the company's shares are short sold. Based on an average daily volume of 967,800 shares, the short-interest ratio is currently 4.7 days.

Institutional Trading of Haemonetics

Several institutional investors have recently modified their holdings of the stock. CWC Advisors LLC. raised its stake in Haemonetics by 33.6% during the 1st quarter. CWC Advisors LLC. now owns 4,118 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 1,035 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Haemonetics by 20.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier's stock worth $60,888,000 after purchasing an additional 165,118 shares during the last quarter. Schwartz Investment Counsel Inc. increased its position in shares of Haemonetics by 148.0% during the first quarter. Schwartz Investment Counsel Inc. now owns 374,500 shares of the medical instruments supplier's stock worth $23,799,000 after purchasing an additional 223,500 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Haemonetics by 22.1% in the 1st quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier's stock valued at $71,070,000 after purchasing an additional 202,609 shares during the last quarter. Finally, Cardinal Capital Management boosted its position in shares of Haemonetics by 8.4% in the 1st quarter. Cardinal Capital Management now owns 19,815 shares of the medical instruments supplier's stock valued at $1,259,000 after purchasing an additional 1,531 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Up 2.6 %

Shares of Haemonetics stock traded up $1.55 during trading on Thursday, hitting $61.89. 413,782 shares of the stock were exchanged, compared to its average volume of 689,403. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm's 50-day moving average price is $62.87 and its 200 day moving average price is $72.36. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 24.37, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. Haemonetics has a 12-month low of $55.30 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on HAE shares. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and lowered their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC lowered their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Finally, StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.